Asset Management One Co. Ltd. Increases Stock Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Asset Management One boosted its stake in Halozyme by 1,358% in Q4, ending the period with 24,844 shares valued at about $1.71 million per its latest Form 13F filing.
• Halozyme posted a sharp EPS miss, reporting ($0.24) versus analysts' $1.92 estimate while revenue of $451.8 million beat expectations and rose 51.6% year‑over‑year.
• Company insiders have been net sellers recently—118,857 shares (~$8.28 million) sold in the past three months (including CEO and COO sales)—leaving insiders with roughly 2.5% ownership.

Asset Management One Co. Ltd. increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1,358.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,844 shares of the biopharmaceutical company's stock after buying an additional 23,140 shares during the period. Asset Management One Co. Ltd.'s holdings in Halozyme Therapeutics were worth $1,713,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in HALO. Root Financial Partners LLC acquired a new position in Halozyme Therapeutics during the third quarter worth $25,000. Larson Financial Group LLC raised its position in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 343 shares during the period. Richardson Financial Services Inc. raised its position in Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 198 shares during the period. Clearstead Advisors LLC raised its position in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company's stock worth $37,000 after acquiring an additional 265 shares during the period. Finally, Penserra Capital Management LLC acquired a new position in Halozyme Therapeutics during the third quarter worth $52,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $66.59 on Friday. The firm has a 50-day simple moving average of $67.43 and a 200-day simple moving average of $68.62. The stock has a market capitalization of $7.89 billion, a price-to-earnings ratio of 26.74, a price-to-earnings-growth ratio of 0.28 and a beta of 1.03. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $1.92 by ($2.16). The business had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. Halozyme Therapeutics's quarterly revenue was up 51.6% on a year-over-year basis. During the same quarter last year, the company earned $1.26 earnings per share. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $63.50, for a total value of $635,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at approximately $48,754,030. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the company's stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the sale, the chief operating officer directly owned 7,055 shares of the company's stock, valued at $477,200.20. This represents a 55.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 118,857 shares of company stock valued at $8,279,587 in the last three months. 2.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Weiss Ratings cut Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a report on Tuesday, February 24th. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a report on Thursday, February 19th. TD Cowen reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Finally, Benchmark increased their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $78.56.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.